The boron-oxygen core of borinate esters is responsible for the store-operated calcium entry potentiation ability.
BACKGROUND
Store-Operated Calcium Entry (SOCE) is the major Ca2+ ion entry pathway in lymphocytes and is responsible of a severe combined immunodeficiency (SCID) when deficient. It has recently been observed or highlighted in other cell types such as myoblasts and neurons, suggesting a wider physiological role of this pathway. Whereas Orai1 protein is considered to be the channel allowing the SOCE in T cells, it is hypothesized that other proteins like TRPC could associate with Orai1 to form SOCE with different pharmacology and kinetics in other cell types. Unraveling SOCE cell functions requires specific effectors to be identified, just as dihydropyridines were crucial for the study of Ca2+ voltage-gated channels, or spider/snake toxins for other ion channel classes. To identify novel SOCE effectors, we analyzed the effects of 2-aminoethyl diphenylborinate (2-APB) and its analogues. 2-APB is a molecule known to both potentiate and inhibit T cell SOCE, but it is also an effector of TRP channels and endoplasmic reticulum Ca2+-ATPase.


RESULTS
A structure-function analysis allowed to discover that the boron-oxygen core present in 2-APB and in the borinate ester analogues is absolutely required for the dual effects on SOCE. Indeed, a 2-APB analogue where the boron-oxygen core is replaced by a carbon-phosphorus core is devoid of potentiating capacity (while retaining inhibition capacity), highlighting the key role of the boron-oxygen core present in borinate esters for the potentiation function. However, dimesityl borinate ester, a 2-APB analogue with a terminal B-OH group showed an efficient inhibitory ability, without any potentiating capacity. The removal or addition of phenyl groups respectively decrease or increase the efficiency of the borinate esters to potentiate and inhibit the SOCE. mRNA expression revealed that Jurkat T cells mainly expressed Orai1, and were the more sensitive to 2-APB modulation of SOCE.


CONCLUSIONS
This study allows the discovery of new boron-oxygen core containing compounds with the same ability as 2-APB to both potentiate and inhibit the SOCE of different leukocyte cell lines. These compounds could represent new tools to characterize the different types of SOCE and the first step in the development of new immunomodulators.
INSERM UMR-S 940, Institut Universitaire d'Hématologie - Université Denis Diderot Paris 7, Hôpital Saint Louis, Paris, France. olivier.dellis@inserm.fr
Olivier
O
Dellis
Pierre
P
Mercier
Christine
C
Chomienne
D001896:Boron Compounds / Q000737:chemistry / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D015220:Calcium Channels / Q000235:genetics / Q000378:metabolism*; D000252:Calcium-Transporting ATPases / Q000037:antagonists & inhibitors; D002460:Cell Line; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D019169:Jurkat Cells; D015394:Molecular Structure; D000071740:ORAI1 Protein; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019284:Thapsigargin / Q000494:pharmacology; D020298:U937 Cells
C538758:2-aminoethyl diphenylborinate; D001896:Boron Compounds; D015220:Calcium Channels; D004791:Enzyme Inhibitors; D000071740:ORAI1 Protein; C510746:ORAI1 protein, human; D019284:Thapsigargin; D000252:Calcium-Transporting ATPases; D002118:Calcium
J Physiol. 2009 Jun 15;587(Pt 12):2903-18
19403622
Cancer Control. 2003 Sep-Oct;10(5):361-9
14581890
J Biochem. 1997 Sep;122(3):498-505
9348075
J Biol Chem. 1985 Mar 25;260(6):3440-50
3838314
EMBO J. 1997 Jun 2;16(11):3078-88
9214625
J Biol Chem. 1997 Oct 17;272(42):26103-9
9334174
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4682-7
17360584
J Biol Chem. 1987 Oct 5;262(28):13558-66
3115980
Mol Pharmacol. 2007 Nov;72(5):1258-68
17673572
Mol Pharmacol. 2001 Sep;60(3):541-52
11502886
J Physiol. 2008 Jul 1;586(13):3061-73
18403424
Eur J Biochem. 2002 Aug;269(15):3678-87
12153564
J Biol Chem. 2002 Feb 22;277(8):6044-50
11744714
Nat Immunol. 2001 Apr;2(4):316-24
11276202
Nat Cell Biol. 2006 Jul;8(7):771-3
16733527
Cell Calcium. 2003 Jul;34(1):97-108
12767897
J Biol Chem. 2004 Aug 20;279(34):35741-8
15194687
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4040-5
16537481
Mol Pharmacol. 2006 Jan;69(1):247-56
16214957
Mol Pharmacol. 2005 Sep;68(3):758-62
15933213
J Biol Chem. 2006 Aug 25;281(34):24979-90
16807233
Expert Opin Drug Discov. 2008 Jul;3(7):787-800
23496221
J Neurosci. 2004 Jun 2;24(22):5177-82
15175387
Nature. 2006 May 11;441(7090):179-85
16582901
Mol Cancer. 2009 Aug 03;8:59
19650915
ChemMedChem. 2009 May;4(5):706-18
19330784
Biochem Biophys Res Commun. 2007 Jan 12;352(2):277-82
17140548
Chem Biol. 2001 Aug;8(8):739-58
11514224
Expert Opin Ther Targets. 2008 Apr;12(4):391-413
18348677
J Physiol. 2001 Oct 1;536(Pt 1):3-19
11579153
Br J Pharmacol. 1994 Nov;113(3):861-8
7858878
J Biol Chem. 2006 Jul 28;281(30):20661-20665
16766533
Cell Calcium. 2007 Aug;42(2):213-23
17350680
Cell Mol Life Sci. 2001 Apr;58(4):596-624
11361094
Cell Calcium. 2001 Feb;29(2):111-6
11162848
Bioorg Med Chem Lett. 1998 Feb 17;8(4):333-8
9871680
Nature. 2007 Mar 15;446(7133):284-7
17361175
J Biol Chem. 2010 Jun 18;285(25):19173-83
20395295
Cell Calcium. 2001 Aug;30(2):117-29
11440469
Ann N Y Acad Sci. 1995 Sep 7;766:31-43
7486679
Methods. 2008 Nov;46(3):204-12
18929662
Curr Biol. 2007 May 1;17(9):794-800
17442569
Biochem Biophys Res Commun. 2003 Nov 28;311(4):1117-32
14623298
J Biol Chem. 2007 Jun 1;282(22):16232-43
17293345
Bioorg Med Chem Lett. 2010 Feb 15;20(4):1395-8
20097561
J Biol Chem. 2005 Apr 22;280(16):15928-41
15722340
J Biol Chem. 2002 Mar 1;277(9):6915-22
11741932
Pflugers Arch. 2008 Nov;457(2):377-87
18546016